Quantum Biopharma Ltd (QNTM) Stock Price, Quote & News

Company Profile

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. It operates through two segments, Biopharmaceutical Innovation and Strategic Investments. The company researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. Its lead compound is Lucid-MS, a patented new chemical entity that is...

Industry: Biotechnology

Sector: Healthcare

Phone: 833 571 1811

Website: www.quantumbiopharma.com

Address:

55 University Avenue, Suite 1003, Toronto, Canada

tenbaggerz Apr. 30 at 6:18 AM

$AKAN move profits to $QNTM

0 · Reply

Vapor83 Apr. 30 at 5:19 AM

$GNS $QNTM gets an IND approval today, tomorrow, or Monday - buy now enjoy the bump, and buy more cheap $GNS

0 · Reply

StockScanners Apr. 30 at 4:00 AM

$QNTM reached 5.70

0 · Reply

Vapor83 Apr. 30 at 3:16 AM

$QNTM 13,542 watchers, but almost no participation in this board

0 · Reply

Vapor83 Apr. 30 at 12:21 AM

$QNTM $700M lawsuit, if successful, equals approximately $120/share

0 · Reply

Vapor83 Apr. 30 at 12:19 AM

$QNTM Key drivers favoring settlement here: • QNTM has already cleared a major hurdle: the court largely denied the defendants’ joint motion to dismiss in April 2026. Surviving this stage significantly increases leverage for plaintiffs and settlement pressure on defendants. • Discovery (expected to ramp up mid-to-late 2026) will involve production of extensive trading records, order data, and potentially depositions. In spoofing cases, this data can be damaging if patterns of large canceled orders are evident. • Defendants are major Canadian banks’ brokerage arms. They have strong incentives to limit negative publicity, legal fees, and any precedent that could invite more lawsuits or regulatory attention. • The company operates on a contingency-fee basis with experienced counsel and has a parallel shareholder class action, which can add collective pressure.

0 · Reply

Vapor83 Apr. 30 at 12:18 AM

$QNTM Banks and broker-dealers frequently settle spoofing or market manipulation allegations to avoid prolonged discovery (which can expose internal trading data, algorithms, and communications) and potential regulatory scrutiny. Regulatory spoofing cases (e.g., JPMorgan’s $920M CFTC settlement, Scotiabank, TD Securities, BofA) almost always resolve via settlement rather than contested trials.

0 · Reply

Vapor83 Apr. 30 at 12:18 AM

$QNTM Over 90% of cases that survive a motion to dismiss ultimately settle, rather than proceeding to trial. Trials in these complex matters are rare due to high costs, uncertainty, and reputational risks.

0 · Reply

Vapor83 Apr. 30 at 12:17 AM

$QNTM The probability that the defendants (CIBC World Markets and RBC Dominion Securities) will seek to settle Quantum BioPharma’s (QNTM) $700M+ spoofing lawsuit is moderately high — roughly in the 60-80% range — once discovery advances meaningfully. This is an educated estimate based on patterns in securities litigation and spoofing-related cases, not a precise prediction. No public statements from the parties indicate imminent settlement talks as of late April 2026.

0 · Reply